



# Don't believe everything! Read carefully! All that glitters is *not* gold!



TURIN

 $24^{\text{th}}-26^{\text{th}}$ 

2019

Fabio Barili, M.D., Ph.D., M.Stat., F.E.S.C.

Staff surgeon | Department of Cardiac Surgery, S. Croce Hospital, Cuneo, Italy.

Vice-Director | Scientific Committee of the Italian Society of Cardiac Surgery

Director | Task force of Methodology, the European Association of Cardio-Thoracic Surgery

Deputy Statistical Editor | The Journal of Thoracic and CardioVascular Surgery







# **Disclosures**

## FB receives consulting fees from Abbott Medical





# **Background (1)**

## The indication for TAVI was expanded to intermediate risk patients on the basis of the major trials

- I	с
I.	с
1	в
1	В
i.	в
ПЬ	с
ШЬ	с

Available data from randomized controlled trials and large registries in elderly patients at increased surgical risk show that TAVI is superior in terms of mortality to medical therapy in extreme-risk patients,<sup>91</sup> non-inferior or superior to surgery in high-risk patients<sup>94–97</sup> and noninferior to surgery and even superior when transfemoral access is possible in intermediate-risk patients.<sup>98–102</sup> In the two large studies on intermediate risk, the mean ages of patients were 82 and 80 years,<sup>99,102</sup> mean STS scores were 5.8% and 4.5%<sup>99,102</sup> and a high percentage were considered frail. Thus the results are valid only for comparable patient groups. Overall, rates of vascular complications, pacemaker









# Background (1)

# TAVI, what's happening at follow-up?



## **TRIALS SAY OK**

Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients



#### HR (95% CI) Tria DADTNED 14 0.90 (0.71 - 1.15) US CoreValue high re 0.79 (0.61 - 1.01) 0.72 (0.33 - 1.59) PARTNER 24 0.92 (0.74 - 1.13) 0.98 (0.72 - 1.34) 0.41 (0.14 - 1.17) PARTNER Evolut low risk 0.83 (0.41 - 1.67) 0 88 (0 78 - 0 99) 0.03 maeneity =2<0.001 n = 0.727 0.5 Favours TAV .0% for high-, intermediate-, and low surgical risk trials, respectively. Transcatheter aortic valve implantation wa ed with a significant reduction of all-cause mortality compared to SAVR (hazard ratio [HR] 0.88 [95% confiace interval (CI) 0.78-0.991, P=0.030; an effect that was conistent across the entire spe scatheter aortic valve implantatio European Heart Journal (2019) 0, 1-11 vs. surgical aortic valve replacement for ent of symptomatic severe a osis: an updated meta-analysis

### META SAY "WOW"



In a new study, use of transcatheter rather than surgical aortic valve replacement (TAVR/SAVR) reduced the risk of early death in low-risk patients with severe aortic stenosis, calling into question whether TAVR should be the preferred option.

In the pooled analysis of 4 randomized trials involving 2887 patients at low surgical risk, the 1-year risks with TAVR and SAVR for all-cause death were 21% vs 3.5% (relative risk [RR], 0.6f; 95% CI, 0.39 - 0.96) and were 1.6% vs 2.9% for cardiovascular death (RR, 0.55; 95% CJ, 0.33 - 0.90).

The magnitude of relative risk reduction was similar in the recently reported pivotal PARTNER 3 and Evolut Low Risk trials, which were included in this study along with the 2015 NOTION trial and a post-hoc SURTAVI analysis. The four trials have shown TAVR is noninferior or superior to SAVR on composite primary endpoints that included mortality; however, none were adequately powered to detect mortality differences in and of themselves, the authors reported in the September 24 issue of the *Journal of the American College of Cardiology*.



# Top of the pyramid of evidence! But...







**Background (1)** 


# ...there could be some limitations!

## **RC TRIALS**

<u>Composite outcomes</u>: underpowered for singular outcomes

Not homogeneous definition of outcomes (neurologic event,...)

Sponsorship: could it be a bias?





# **Background (2)**

### Prospective randomized studies are mainly made by companies

Surveys of randomized trials published between 1990 and 2000 raised awareness in the medical community that trials funded by for-profit organizations were more likely to report positive findings than those funded by not-for-profit organizations.

Contemporary data has confirmed that incentives surrounding for-profit organizations have the potential to influence clinical trial outcomes.

Table 2. Proportion of Trials Significantly Favoring Newer Treatments Over Standard of No./Total %							
Trials	Not-for-Profit (n = 104)	Not-for-Profit and For-Profit (n = 62)	For-Profit (n = 137)	P for Trend			
All	51/104 (49.0)	35/62 (56.5)	92/137 (67.2)	.005			
Clinical end points	19/55 (34.6)	24/44 (54.6)	64/96 (66.7)	<.001			
Drug	17/43 (39.5)	24/46 (54.4)	74/113 (65.5)	.002			
Device	4/8 (50.0)	9/13 (69.2)	14/17 <mark>(</mark> 82.4)	.07			



Attempts to explain this phenomenon have focused largely on design bias, interpretation bias, data suppression, and differential data quality.

Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005 JAMA. 2006;295:2270-2274







# LET'S SEE

# OUTCOMES

# LANDMARK

# **INCLUSION CRITERIA**

# POTENTIAL BIAS FOR MISCLASSIFICATION

# **PROPENSITY SCORE**

**META-ANALYSIS OF HRs** 







TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2

# **OUTCOMES**

## **PRIMARY OUTCOMES IN TAVI/SAVR RANDOMIZED STUDIES**

## What it is suggested by guidelines

		consensus document* (J Thorac Cardiovasc Surg 2013;145:6-23)
Guidelines for reporting mortality and morbidity after cardiac valve interventions J Thorac Cardiovasc Surg 2008;135:732-8	COMPOSITE ENDPOINTS	TABLE 11. Composite endpoints Device success
MORTALITY	LANDMARK AT 30-day	Absence of procedural mortality AND Correct positioning of a single prosthetic heart valve into the proper anatomical location AND Intended performance of the prosthetic heart valve (no prosthesis– patient mismatch* and mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s, AND no moderate or severe prosthetic valve
Valve—related		regurgitation*) Early safety (at 30 days)
Cardiac		All-cause mortality All stroke (disabling and nondisabling)
		Life-threatening bleeding Acute kidney injury—Stage 2 or 3 (including renal replacement
All cause		therapy)
		Coronary artery obstruction requiring intervention Major vascular complication
		Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or
MORBIDITY		SAVR) Clinical efficacy (after 30 days)
		All-cause mortality
		All stroke (disabling and nondisabling) Requiring hospitalizations for valve-related symptoms or worsening
Structural valve deterioration		congestive heart failure†
Non-structural dysfunction		NYHA class III or IV
		Valve-related dysfunction (mean aortic valve gradient $\geq$ 20 mm Hg, EOA $\leq$ 0.9–1.1 cm <sup>2</sup> ‡ and/or DVI <0. 35 m/s, AND/OR moderate or
Thrombosis		severe prosthetic valve regurgitation*)
Embolism		Time-related valve safety Structural valve deterioration
		Valve-related dysfunction (mean aortic valve gradient $\geq$ 20 mm Hg,
Bleeding		EOA $\leq 0.9$ -1.1 cm <sup>2</sup> $\ddagger$ and/or DVI $< 0.35$ m/s, AND/OR moderate
Endocarditis		or severe prosthetic valve regurgitation*) Requiring repeat procedure (TAVI or SAVR)
		Prosthetic valve endocarditis
Redo		Prosthetic valve thrombosis Thrombo-embolic events (eg, stroke)
		VARC bleeding, unless clearly unrelated to valve therapy (eg, trauma)



# **Outcomes**

# PRIMARY OUTCOMES INTAVI/SAVR RANDOMIZED STUDIES

	<b>PARTNER 1A</b> (6)	CoreValve HR (7)	<b>PARTNER 2A</b> (10)	NOTION (9)	SURTAVI (8)
Time of recruitment	May 2007–August 2009	February 2011–December 2012	December 2011 -November 2013	December 2009-April 2013	June 2012 – June 2016
THV	SAPIEN	CoreValve	SAPIEN XT	CoreValve	CoreValve
Primary e ndpoint	All-cause death at 1 year	All-cause death at 1 year	All-cause death or diasbling stroke at 2 years	All-cause death, disabling stroke or myocardial infarction at 1 year	All-cause death or disabling stroke at 2 years

Front. Cardiovasc. Med. 5:92. doi: 10.3389/fcvm.2018.00092

Composite endpoints different among studies and from guidelines

Durability at two years? What about valve-related death?

Landmark at 30-days? (Does the risk profile change over time?)







## **Outcomes**


## **EX: SURTAVI COMPOSITE OUTCOMES**

#### TRIAL END POINTS

The primary end point was a composite of <u>death</u> from any cause or disabling stroke at 24 months. (Trial end-point definitions are provided in Table S4 in the Supplementary Appendix.) Disabling stroke was defined according to the criteria of the Valve Academic Research Consortium-2 (VARC-2).<sup>10</sup> N Engl J Med 2017;376:1321-31.

Outcome		30 Days			12 Month	s		24 Months	
	TAVR	Surgery	95% Credible Interval	TAVR	Surgery	95% Credible Interval	TAVR	Surgery	95% Credible Interval
					percent				
Death from any cause or disabling stroke	2.8	3.9	-2.8 to 0.7	8.1	8.8	-3.5 to 2.1	12.6	14.0	-5.2 to 2.3
Death from any cause	2.2	1.7	-0.9 to 1.8	6.7	6.8	-2.7 to 2.4	11.4	11.6	-3.8 to 3.3
Cardiovascular	2.0	1.7	-1.0 to 1.6	4.8	5.5	-2.9 to 1.5	7.7	8.0	-3.3 to 2.6
Valve-related	0.1	0.1	-0.3 to 0.3	0.1	0.3	-0.7 to 0.3	0.2	0.4	-0.9 to 0.5
Aortic-valve reintervention	0.9	0.2	-0.1 to 1.4	2.1	0.5	0.4 to 2.7	2.8	0.7	0.7 to 3.5
All stroke and TIA	4.5	6.5	-4.2 to 0.3	8.2	8.6	-3.1 to 2.4	10.0	11.0	-4.2 to 2.2
All stroke	3.4	5.6	-4.2 to -0.2	5.4	6.9	-3.9 to 0.9	6.2	8.4	-5.0 to 0.4
Disabling	1.2	2.5	-2.6 to 0.1	2.2	3.6	-3.1 to 0.4	2.6	4.5	-4.0 to 0.1
Nondisabling	2.2	3.1	-2.5 to 0.6	3.7	3.9	-2.2 to 1.7	4.4	4.7	-2.6 to 1.9
TIA	1.5	1.1	-0.7 to 1.5	3.2	2.0	-0.4 to 2.8	4.3	3.1	-0.9 to 3.2
Myocardial infarction	0.9	1.0	-1.0 to 0.9	2.0	1.6	-0.9 to 1.8	2.8	2.2	-1.1 to 2.4
Hospitalization for aortic-valve- related disease	2.9	4.2	-3.1 to 0.5	8.5	7.6	-1.8 to 3.6	13.2	9.7	0.1 to 7.0
MACCE	5.7	7.4	-4.0 to 0.7	13.2	12.8	-2.9 to 3.7	18.6	18.6	-4.2 to 4.2

We determined that TAVR would be declared noninferior to surgery for the primary outcome if the posterior probability of noninferiority with a margin of 0.07 was more than 0.971,







# **Outcomes**

# **EX: PARTNER 2A ENDPOINTS**

#### END POINTS

The primary end point was a nonhierarchical composite of death from any cause or disabling stroke at 2 years in the intention-to-treat population; all the patients were followed for at least

Table 2. Clinical End Points at 30 Days, 1 Year, and 2 Years.*									
End Point		At 30 Days			At 1 Year			At 2 Years	
	TAVR (N=1011)	Surgery (N = 1021)	P Value	TAVR (N=1011)	Surgery (N=1021)	P Value	TAVR (N=1011)	Surgery (N=1021)	P Value
	no. of pat	ients (%)		no. of pa	tients (%)		no. of pat	ients (%)	
Death from any cause or disabling stroke	62 (6.1)	80 (8.0)	0.11	145 (14.5)	160 (16.4)	0.24	192 (19.3)	202 (21.1)	0.33
Death									
From any cause	39 (3.9)	41 (4.1)	0.78	123 (12.3)	124 (12.9)	0.69	166 (16.7)	170 (18.0)	0.45
From cardiac causes	33 (3.3)	32 (3.2)	0.92	70 (7.1)	77 (8.1)	0.40	97 (10.1)	104 (11.3)	0.38
Not from cardiac causes	6 (0.6)	9 (0.9)	0.41	53 (5.6)	47 (5.2)	0.71	69 (7.4)	65 (7.4)	0.98
Neurologic event									
Any event	64 (6.4)	65 (6.5)	0.94	99 (10.1)	93 (9.7)	0.76	121 (12.7)	103 (11.0)	0.25
Transient ischemic attack	9 (0.9)	4 (0.4)	0.17	23 (2.4)	16 (1.8)	0.38	34 (3.7)	20 (2.3)	0.09
Any stroke	55 (5.5)	61 (6.1)	0.57	78 (8.0)	79 (8.1)	0.88	91 (9.5)	85 (8.9)	0.67
Disabling stroke	32 (3.2)	43 (4.3)	0.20	49 (5.0)	56 (5.8)	0.46	59 (6.2)	61 (6.4)	0.83
Nondisabling stroke	23 (2.3)	18 (1.8)	0.43	30 (3.0)	24 (2.5)	0.44	33 (3.4)	27 (2.9)	0.51
Rehospitalization	64 (6.5)	62 (6.5)	0.99	142 (14.8)	135 (14.7)	0.92	183 (19.6)	156 (17.3)	0.22
Death from any cause or rehospitalization	99 (9.8)	101 (10.2)	0.78	234 (23.4)	225 (23.3)	0.97	303 (30.5)	281 (29.6)	0.67
Death from any cause, any stroke, or rehospitalization	140 (13.9)	153 (15.3)	0.37	274 (27.4)	276 (28.3)	0.64	344 (34.6)	326 (33.9)	0.75
Myocardial infarction	12 (1.2)	19 (1.9)	0.22	24 (2.5)	29 (3.0)	0.47	33 (3.6)	37 (4.1)	0.56
Major vascular complication	80 (7.9)	51 (5.0)	0.008	84 (8.4)	54 (5.3)	0.007	86 (8.6)	55 (5.5)	0.006
Life-threatening or disabling bleeding	105 (10.4)	442 (43.4)	<0.001	151 (15.2)	460 (45.5)	<0.001	169 (17.3)	471 (47.0)	<0.001
Acute kidney injury	13 (1.3)	31 (3.1)	0.006	32 (3.4)	48 (5.0)	0.07	36 (3.8)	57 (6.2)	0.02
New atrial fibrillation	91 (9.1)	265 (26.4)	< 0.001	100 (10.1)	272 (27.2)	< 0.001	110 (11.3)	273 (27.3)	< 0.001
New permanent pacemaker	85 (8.5)	68 (6.9)	0.17	98 (9.9)	85 (8.9)	0.43	114 (11.8)	96 (10.3)	0.29
Endocarditis	0	0	-	7 (0.8)	6 (0.7)	0.84	11 (1.2)	6 (0.7)	0.22 🦯
Aortic-valve reintervention	4 (0.4)	0	0.05	11 (1.2)	4 (0.5)	0.10	13 (1.4)	5 (0.6)	0.09

# Table II Composite endpoints Clinical efficacy (after 30 days) All eques montality

All-cause mortality
 All stroke (disabling and non-disabling)
 Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure<sup>b</sup>
 NYHA class III or IV
 Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9–1.1 cm<sup>2c</sup> and/or DVI <0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitation<sup>a</sup>)

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document<sup>1</sup>

#### Crude reoperation rate











TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# **Outcomes**

# **5 YEARS OUTCOMES FROM THE PARTNER 2A TRIAL**





Hazard of Re-hospitalization at 5 years 28% higher in TAVI Hazard of Re-Intervention at 5 years 4 times higher in TAVI

**DURABILITY IS CRITICAL ISSUE ......** 





TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# **Outcomes**

# ...BUT WE ARE FORGETTING IT!

TABLE 2 | Overview of currently active randomized trials on TAVI vs. SAVR in low to intermediate risk patients with severe aortic stenosis.

	DEDICATE	NOTION 2	PARTNER 3	CoreValve low risk	
Reference/NCT number	Clinicaltrials.gov/NCT03112980	Clinicaltrials.gov/NCT02825134	Clinicaltrials.gov/NCT02675114	Clinicaltrials.gov/NCT02701283	
Study start date	2017	2016	2016	2016	<b>—</b>
Study status	Recruiting	Recruiting	Recruiting	Recruiting	Feasibility
Estimated study completion date	2024	2024	2027	2026	
Patients' risk profile	STS-PROM 2-6%	Patient age $\leq$ 75 years and STS-PROM $<$ 4%	STS-PROM <4%	Operative risk <3%	Safety
Study arms	TAVI* vs. SAVR* (1:1 randomization)	TAVI* vs. SAVR* (1:1 randomization)	TAVI (SAPIEN 3) vs. SAVR* (1:1 randomization)	TAVI (CoreValve Evolut R) vs. SAVR* (1:1 randomization)	,
Estimated enrollment	1,600	992	1,328	1,200	
Primary Outcome	• Efficacy endpoint: Overall survival at 5 years	All-cause mortality, myocardial infarction or stroke at 1 year	All-cause mortality, stroke, or re-hospitalization at 1 year	All-cause mortality or disabling	Efficacy: Durability?
	<ul> <li>Safety endpoint: Overall survival at 1 year and 196 deaths (event-driven)</li> </ul>				
Follow up time	5 years	1 year	10 years	10 years	
		(22). Overall, the	incidence of structural valv	e degeneration and Front	. Cardiovasc. Med. 5:92.

(22). Overall, the incidence of structural valve degeneration and aortic valve re-intervention were low but will naturally become an issue as follow-up length and patient numbers increase. Recently published definitions of prosthesis degeneration may aid comprehensive analysis of this important topic (23, 24). To eliminate durability concerns after TAVI, very solid durability data available for surgical bioprostheses over the course of more than a decade will need to be matched (25).

Front. Cardiovasc. Med. 5:92. doi: 10.3389/fcvm.2018.00092



### TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# **Outcomes**

# ....and the choice is driven by the sample size need

#### ORIGINAL ARTICLE

Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients



#### END POINTS

The primary end point was a composite o<u>f death</u> from any cause, stroke, or rehospitalization at 1 year after the procedure. All the patients unWhy use composites? The main advantage of this approach is increased statistical efficiency. By measuring more than one result and combining the data in a single outcome, researchers have an easier time showing a statistically significant difference between the treatment group and controls. This allows for studies that require fewer patients, take less time, and ultimately are more cost-effective. However, this approach can also open the door to misdirection and statistical sleight of hand.

# Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials

Conclusion The use of composite end points in cardiovascular trials is frequently complicated by large gradients in importance to patients and in magnitude of the effect of treatment across component end points. Higher event rates and larger treatment effects associated with less important components may result in misleading impressions of the impact of treatment.

# BMJ

### WHAT THIS STUDY ADDS

Almost half of a sample of recent prominently published cardiovascular trials used composite end points, which were often inadequately reported and showed large gradients in importance to patients

End points of least importance to patients typically contributed most events

Composite end points, as currently used in cardiovascular trials, may often be misleading






**TURIN** October  $24^{\text{th}}-26^{\text{th}}$ 2019

# **OUTCOMES & LANDMARK**

5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial Lancet 2015; 385: 2477-84

### WHY?

The assumption of hazardproportionality in COX was violated



Kaplan-Meier analysis of all-cause death in the intention-to-treat population (A) and by landmark analysis (B);









# **Outcomes: Landmark at 30 days**


### **PARTNER 2A ENDPOINTS**




### SURTAVI ENDPOINTS



### **EVOLUT R ENDPOINTS**



### **PARTNER 3 ENDPOINTS**



## NO LANDMARKING HAS BEEN PERFORMED....

Differences are in the 30 day-2 months

**CURVES ARE PARALLEL AFTER A COUPLE OF MONTHS** 

**PROPORTIONALITY OF HAZARDS COULD BE NOT RESPECTED** 



**TURIN** 


October 24<sup>th</sup>-26<sup>th</sup>

2019



### TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# **Outcomes: Landmark Analysis at follow-up**






**TURIN** 

October 24<sup>th</sup>-26<sup>th</sup>

2019


# **Outcomes: Landmark Analysis at follow-up**





TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# **Outcomes: Landmark Analysis at follow-up**









# **INCLUSION CRITERIA**

Randomization, when properly conducted, avoids bias by distributing both known and unknown

patient characteristics between the experimental conditions on the basis of the play of chance.

BMJ 2013;347:f6409 doi: 10.1136/bmj.f6409 (Published 11 November 2013)

# **ASSOCIATED PROCEDURES | TREATMENT GROUPS**

PARTNER 2 Trial SURTAVI Trial		EVOLUT R Trial		PARTNER 3 Trial			
Surgery	9.1% concomitant 14.5% CABG	Surgery	27.8%	Surgery	26.2%	Surgery	26.4%
TAVR	3.9% PCI	TAVR	14.5%	TAVR	6.9%	TAVR	7.9%
P-value < 0.0001		P-value < 0.0001		P-value < 0.0001		P-value < 0.0001	

## **ASSOCIATED PCI/CABG | TREATMENT GROUPS**

PARTNER 2 Trial	SURTAVI Trial	EVOLUT R Trial	PARTNER 3 Trial
Surgery 14.5% TAVR 3.9%	Surgery 22.1% TAVR 14.5%	Surgery 13.6% TAVR 6.9%	Surgery 12.8% TAVR 6.5%
P-value < 0.0001	P-value < 0.0001	<mark>P-value &lt; 0.0001</mark>	P-value 0.0012


# **HOMOGENEOUS GROUPS?**







# Are the surgical arms homogeneous?





**TURIN** 

October 24<sup>th</sup>-26<sup>th</sup>

2019





TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# **OTHER POTENTIAL BIASES? DATA MISCLASSIFICATION?**



#### News > Medscape Medical News

### Deaths Linked to Transcatheter Valve Cases May Be 'Underreported'

Batya Swift Yasgur MA, LSW October 15, 2019



Deaths associated with some transcatheter valve-repair procedures may be underreported in a US Food and Drug Administration (FDA) adverse events database, leaving a misleading picture of the number of associated fatalities, a new report suggests.

It found that <u>17.5%</u> of deaths associated with the *SAPIEN 3* (Edwards Lifesciences) transcatheter valve and 24.7% of those associated with *MitraClip* (Abbott Vascular) were misclassified as "injury" or "malfunction" events in the FDA's Manufacturer and User Facility Device Experience (MAUDE) database.

"We found that a significant number of deaths associated with these high-risk cardiac devices were not correctly classified," senior author Rita F. Redberg, MD, MSc, told *theheart.org* / *Medscape Cardiology.* 

"Therefore, clinicians, patients, or anyone searching MAUDE — the primary source for adverse event data — to determine how many deaths were reported associated with these devices would get an <u>erroneously low number</u> for deaths reported to MAUDE, which is already only a small fraction of all adverse events, as most are not reported to MAUDE," said Redberg, from the University of California, San Francisco.

17.5% of DEATHS MISCLASSIFICATED


## MAUDE: ERRONEOUSLY LOW NUMBER OF REPORTED DEATHS







# **PS STUDY ON TAVI vs SAVR: A QUASI-RANDOMIZED STUDY?**



Appendix Figure 4. Time to Event Curves for A. All-Cause mortality, B. All Stroke, C. Composite of allcause mortality and stroke



**TURIN** 

October 24<sup>th</sup>-26<sup>th</sup>

2019






# **META-ANALYSIS. TOP OF PYRAMID OF EVIDENCE!**

Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis

European Heart Journal (2019) **0**, 1–11 doi:10.1093/eurheartj/ehz275



**Conclusion** Compared with SAVR, TAVI is associated with reduction in all-cause mortality and stroke up to 2 years irrespective of baseline surgical risk and type of THV system.



TURIN

October 24<sup>th</sup>-26<sup>th</sup>

2019






TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# **META-ANALYSIS. TOP OF PYRAMID OF EVIDENCE!**

Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis


European Heart Journal (2019) **0**, 1–11 doi:10.1093/eurheartj/ehz275



## 1) HRs and RR together?

ciple and utilized as-treated data, if ITT data were unavailable. Hazard ratios took precedence over risk ratios (RRs) to incorporate time-toevent data and allow for censoring. We derived RR using the number of events and participants in each treatment group when HR were unavailable. Disagreements between reviewers were resolved through consensus or third-party adjudication.

## 2) Proportionality of Hazards?








**TURIN** 

October 24<sup>th</sup>-26<sup>th</sup>

2019

# **META-ANALYSIS. TOP OF PYRAMID OF EVIDENCE!**







# CONCLUSIONS

# ARE YOU SURE THAT EVERYTHING THAT GLITTERS IS GOLD????

# New perspectives: transcatheter aortic valve implantation in the year 2020

In 2020 transcatheter aortic valve implantation (TAVI) will be the default treatment in patients with aortic stenosis European Heart Journal (2015) **36**, 1200–1206

Why is this the case? Because more than half a million patients will have been treated by this technique worldwide, allowing its efficacy, safety, and durability to be assessed.

As a consequence of these good results of TAVI shown in randomized trials such as PARTNER 2 and SURTAVI and also in large dynamic registries, the technique will be performed in intermediate, and probably, low-risk patients'. Surgical valve replacement will be limited to patients with a contraindication to TAVI or those who need combined cardiac or aortic surgery.



 The current findings at 5 years mandate re-examination at later timepoints; follow-up has been extended in PARTNER 2A to 10 years